EU Drug Regulators To Bring 'Predictability' To Requests For Post-Authorization Efficacy Studies
This article was originally published in SRA
Executive Summary
The European Medicines Agency is getting closer to releasing a scientific guideline that clarifies in which situations drug regulators might impose a post-authorization efficacy study (PAES) on a company and what a PAES should involve.